Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Weight loss drugs linked to higher risk of eye damage in diabetic patients

Study finds medicines such as Ozempic associated with greater risk of developing age-related macular degeneration

The Guardian - UK

Tudor Pro, Uno-X and TotalEnergies scheduled to debut in Maryland Cycling Classic in September

Early commitments for women's race include Canyon-SRAM zondacrypto and EF Education-Oatly

Cycling News

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies

From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of trouble.

Fortune

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

MarketBeat

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’

Edward Fanelli, 57, shared his regrets about taking Ozempic after he was diagnosed with a rare eye condition.

The Independent UK

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Investors Look on the Bright Side

A generally good week closes on another positive note, as investors, traders and speculators look for fresh catalysts.

Kiplinger

Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?

Novo Nordisk stock sinks as CEO Lars Fruergaard announces his resignation. Analysts are not happy with his departure but continue to see significant upside in NVO shares.

Barchart

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

International Business Times

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

Euronews

Is It Time to Buy the Dip in Novo Nordisk Stock?

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

MarketBeat

Europe's Biggest 'Green' Methanol Plant Opens In Denmark

Europe's largest "green" methanol plant opened in Denmark on Tuesday, boosting the continent's emissions reduction efforts -- with customers ranging from shipping giant Maersk to toymaker Lego and pharmaceutical firm Novo Nordisk.

International Business Times

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

The Guardian - UK

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Health experts reveal weight-loss jabs can ‘prevent mealtime battles’ for children

Health experts presented findings showing the drugs helped severely obese youngsters shed pounds on top of the diet and lifestyle plan they were already following

Evening Standard

Weight-loss jabs for children ‘are effective and help prevent mealtime battles’

Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings.

Fortune

Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars

Novo Nordisk's CFO says the company is well-placed to respond to an escalation of the global trade war.

The Guardian - UK

Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off

Slowdown will deepen concerns Denmark’s biggest company is losing market share to US rival Eli Lilly

Get all your
news in one place.

100’s of premium titles.
One news app.

Euronews

Novo Nordisk cuts guidance as weight-loss drug market competition grows

Novo Nordisk shares jumped following stronger-than-expected first-quarter earnings, despite the company lowering its growth outlook for 2025 amid intensifying competition in the weight-loss drug markets.

MarketBeat

Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?

Shares of Eli Lilly just got walloped. So, is the company still the name to own in GLP-1s, or are the tables turning on this pharma giant?

MarketBeat

The Top 3 Stock Picks at the World’s Greatest Hedge Fund

See which three stocks the world's most successful hedge fund, which generated returns of +30% for decades, had the biggest stakes in at the end of 2024.

Fortune

CVS customers can get weight-loss drug Wegovy at a discount for cash

But you'll have to pay cash.

Euronews

Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment

There are currently no drugs approved in the European Union to treat the liver condition known as MASH, but a new trial of semaglutide has shown “exciting” results.

The Independent UK

Ozempic is growing in popularity — it’s also sending people to the ER

An analysis of emergency visits related to the active ingredient in drugs like Ozempic and Wegovy has exposed a surprising effect

MarketBeat

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

1 … 9 10 11 12

People

Lars Fruergaard Jørgensen

18 stories

Derren Nathan

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.